Text Size
9833 studies found for:    NCI

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Raloxifene in Preventing Breast Cancer in Premenopausal Women
Condition: Breast Cancer
Interventions: Drug: raloxifene;   Procedure: evaluation of cancer risk factors
2 Completed UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: 7-hydroxystaurosporine;   Drug: prednisone
3 Completed Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma
Conditions: Recurrent Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
4 Suspended
Has Results 		Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: sorafenib tosylate;   Drug: paclitaxel;   Drug: carboplatin
5 Completed Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: gemcitabine hydrochloride
6 Terminated AFP464 in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AFP464;   Other: laboratory biomarker analysis;   Other: pharmacological study
7 Active, not recruiting Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: tamoxifen citrate;   Drug: letrozole;   Biological: bevacizumab
8 Active, not recruiting Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: bortezomib;   Drug: decitabine;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Genetic: DNA methylation analysis;   Genetic: RNA analysis
9 Active, not recruiting Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Conditions: Childhood Burkitt Lymphoma;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Medulloepithelioma;   Childhood Meningioma;   Childhood Mixed Glioma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Childhood Oligodendroglioma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Completed Irinotecan in Treating Patients With Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: irinotecan hydrochloride
11 Completed Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
Conditions: Long-term Effects Secondary to Cancer Therapy in Children;   Sarcoma
Interventions: Procedure: management of therapy complications;   Procedure: quality-of-life assessment
12 Completed Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Biological: apolizumab
13 Terminated SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: semaxanib
14 Completed Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
Conditions: Head and Neck Cancer;   Lung Cancer
Interventions: Other: cytology specimen collection procedure;   Other: immunohistochemistry staining method;   Other: sputum cytology;   Procedure: bronchoscopic and lung imaging studies;   Procedure: bronchoscopy;   Procedure: comparison of screening methods;   Procedure: endoscopic biopsy
15 Active, not recruiting Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: erlotinib hydrochloride;   Drug: irinotecan hydrochloride
16 Completed Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: celecoxib;   Other: laboratory biomarker analysis
17 Completed CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pelitinib;   Drug: temsirolimus
18 Completed VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: docetaxel;   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis;   Other: pharmacological study
19 Active, not recruiting Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Conditions: Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: tipifarnib;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: pegfilgrastim;   Procedure: conventional surgery;   Procedure: axillary lymph node dissection
20 Active, not recruiting Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: high performance liquid chromatography;   Genetic: microarray analysis;   Genetic: RNA analysis;   Other: mass spectrometry;   Genetic: DNA methylation analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years